References
McSwain H, Brodie MF. Fallopian tube occlusion, an alternative to tubal ligation. Tech Vasc Interv Radiol. 2006 Mar;9(1):24-9.
Essure web site. Available at www.essure.com. Accessed April 8, 2007.
"About the Sponge." Today Sponge. Allendale Pharmaceuticals, Inc. 2005. http://www.todaysponge.com. Accessed June 12, 2005.
"Colorectal Cancer Statistics 2005." Cancer Research and Prevention Foundation. http://www.preventcancer.org. Accessed June 13, 2005.
"Lunelle (Monthly Injection." Feminists Women's Health Center. January 30, 2005. http://www.birth-control-comparison.info. Accessed June 12, 2005.
"Efforts to Research and Inform the Public About Nonoxynol-9 and HIV." U.S. Government Accountability Office (GAO). Report to Congressional Requesters. Publication GAO-05-399. March 2005. http://www.global-campaign.org. Accessed June 12, 2005.
"FDA Approves Seasonale Oral Contraceptive" FDA Talk Paper. U.S> Food and Drug Administration. Sept. 5, 2003. http://www.fda.gov. Accessed June 11, 2005.
"FDA proposes new warning for over-the-counter contraceptive drugs containing nonoxynol-9." FDA Talk Paper. U.S. Food and Drug Administration. Jan. 16, 2003. http://www.fda.gov. Accessed June 11, 2005.
The American College of Obstetricians and Gynecologists. http://www.acog.org. Accessed June 12, 2005.
"1998 Guidelines for Treatment of Sexually Transmitted Diseases." Centers for Disease Control and Prevention. MMWR, 1998;Vol. 47;No. RR-1. Accessed August 2001.
Population Reports: "Oral Contraceptives - An Update." Population Information Program, Center for Communication Programs. The Johns Hopkins School of Public Health. Volume XXVIII, Number 1, Spring, 2000. http://www.infoforhealth.org. Accessed June 11, 2005.
Planned Parenthood. http://www.plannedparenthood.org. Accessed June 11, 2005.
"What is Natural Family Planning?" Service for the Regulation of Natality (SERENA). http://www.serena.ca. Accessed June 11, 2005.
Hatcher, R.A., Zieman, M., Nelson, A., Darney P.D., Creinin M.D., Stosur, H.R., Cwiak C. "Managing Contraception." BTG Foundation. . http://www.managingcontraception.com. Accessed June 11, 2005.
"Birth Control Guide" U.S. Food and Drug Administration. Revised December 2003. http://www.fda.gov. Accessed June 11, 2005.
"Birth Control: Comparieng the Choices." Association of Reproductive Health Professionals (ARHP). Updated October 30, 2004. http://www.arhp.org. Accessed June 12, 2005
"Oral Contraceptives and Cancer Risk." National Cancer Institute. Reviewed Feb. 2003. Includes CARE and Collaborative Group on Hormonal Factors in Breast Cancer Study findings. http://cis.nci.nih.gov/fact/3_13.htm. Accessed June 12, 2005.
"Women in the Know (Birth Control Selector and Birth Control Guide)." Ortho-McNeil Pharmaceutical, Inc., 2001. http://www.orthowomenshealth.com. Accessed June 11, 2005.
"Birth Control." Medlineplus Health Information. National Library of Medicine. National Institutes of Health. http://www.nlm.nih.gov. Accessed June 12, 2005.
"FDA Approves first Hormonal Vaginal Contraceptive Ring." FDA Talk Paper. U.S. Food and Drug Administration. Oct. 3, 2001. http://www.fda.gov. Accessed June 11, 2005.
"Ortho Evra" (norelgestromin/ethyl estradiol transdermal system)" Ortho McNeil Pharmaceuticals. http://www.orthoevra.com. Accessed June 12, 2005.
Hatcher, R., Trussell, J., Stewart, F., Nelson, A., Cates, W., Guest, F., & Kowal, D. (2004). Contraceptive technology (18th ed.). New York: Ardent Media, Inc.
"The Shot: Depo Provera" The Feminist Women's Health Center. July 12, 2005. http://www.fwhc.org. Accessed December 2005.
"What causes breast cancer?" The American Cancer Society. September 16. 2005. http://www.cancer.org. Accessed December 2005.
"Class II Special Controls Guidance Document: Labeling for Male Condoms Made of Natural Rubber Latex." U.S. Food and Drug Administration. November 14, 2005. http://www.fda.gov. Accessed December 2005.
Hatcher, R. et al (2004). Contraceptive technology (18th ed). New York: Ardent Media Inc.
World Health Organization (2000). Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use (2nd ed). Geneva, Switzerland: WHO.
"FDA approves new indication for YAZ® to treat emotional and physical symptoms of premenstrual dysphoric disorder." Berlex. October 2006.
| |
|
View References for this Health Topic
|
Create Date: 2/1/02
Date Last Updated: 5/8/07
Review Date: 4/15/06
|
|